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Abstract
Summary Aromatase inhibitors (AIs) are widely used in
women with breast cancer, but they are known to increase
bone loss and risk of fractures. Based on available evidence
and recommendations, an ESCEO working group proposes
specific guidance for the prevention of AIs-induced bone
loss and fragility fractures.
Introduction Aromatase inhibitors (AIs) are now the standard
treatment for hormone receptor-positive breast cancer.
However, deleterious effects of AIs on bone health have been
reported. An ESCEO working group proposes guidance for
the prevention of bone loss and fragility fractures in post-
menopausal women with breast cancer receiving AIs.
Methods A panel of experts addressed the issue of skeletal
effects of AIs and effectiveness of antifracture therapies for
the prevention of AI-induced bone loss and fractures.
Recommendations by national and international organiza-
tions, and experts’ opinions on this topic were evaluated.
Results All aromatase inhibitors are associated with negative
effects on the skeleton, resulting in bone loss and increased
risk of fragility fractures. Current guidelines suggest
approaches that differ both in terms of drugs proposed for
fracture prevention and duration of treatment.
Conclusion The ESCEO working group recommends that
all AI-treated women should be evaluated for fracture risk.
Besides general recommendations, zoledronic acid 4 mg i.v.
every 6 months, denosumab s.c., or possibly oral bisphosph-
onates should be administered for the entire period of AI
treatment to all osteoporotic women (T-score hip/spine <−2.5
or ≥1 prevalent fragility fracture), to women aged ≥75 irre-
spective of BMD, and to patients with T-score <−1.5+≥1
clinical risk factor or T-score <−1.0+≥2 clinical risk factors.
Alternatively, therapy could be considered in patients with a
FRAX-determined 10-year hip fracture probability ≥3%.
Keywords Aromatase inhibitors . Bisphosphonates . Bone
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Introduction
Breast cancer is the most frequent neoplasm in women—
with its incidence still growing—and the first cause of
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cancer mortality among women. Notably, a reduction in
breast cancer mortality has been observed in recent years
[1, 2]. Aromatase inhibitors (AIs) represent the gold standard
adjuvant treatment for postmenopausal women with hormone
receptor-positive breast cancer [3, 4] and for the management
of metastatic disease [5]. AIs have shown significant advan-
tages in terms of progression-free survival and especially
distant recurrence compared to tamoxifen in large randomized
controlled adjuvant therapy trials [6–8]. Furthermore, extend-
ed therapies with AIs (up to 10 years) are increasingly being
introduced in women at higher risk of long-term recurrence,
including patients with positive lymph node disease [9]. The
aromatase enzyme, which is blocked by AIs, converts andro-
gens into estrogens. This conversion is the main source of
endogenous estrogens in postmenopause [10]. Bone loss rep-
resents a classic side effect of AI treatment [11–13]. This issue
is of particular relevance since AI-treated women with breast
cancer who develop a vertebral osteoporotic fracture are often
suspected of metastatic disease, thus leading to additional
investigations and avoidable costs for the health-care system
due to unnecessary diagnostic procedures [14]. Therefore, it is
very important (1) to identify the patients at increased risk of
fractures, and (2) to introduce preventive antifracture treat-
ments in women at increased risk of fracture who undergo
adjuvant hormone therapy with AIs [14]. The American
Society of Clinical Oncology (ASCO) has proposed specific
recommendations regarding this issue, suggesting that all
patients with T-score <−2.5 should start proper antifracture
treatment with bisphosphonates [15]. However, many open
questions still remain unanswered, including a general
increase of fracture risk in women with breast cancer,
their quality of life, the risk of falls, the duration of
antifracture therapy, and vitamin D supplementation.
Given the high incidence of breast cancer in postmenopausal
women and the wide use of prolonged estrogen-suppressive
therapies, the European Society for Clinical and Economical
Aspects of Osteoporosis (ESCEO) working group strongly
believes that it is necessary to manage the long-term effects of
aromatase inhibitors on bone health. This position paper is
aimed at providing physicians (oncologists and specialists in
metabolic bone diseases) with updated guidance integrating
the analysis of the most recent medical literature and recom-
mendations from international societies or expert panels.
Methods
A panel of experts addressed the issue of skeletal effects of
AIs and effectiveness of antifracture therapies for the pre-
vention of AI-induced bone loss and fractures through a
systematic search of published literature on PubMed. The
results of available descriptive, cross-sectional, and prospec-
tive studies related to pathogenesis and severity of skeletal
effects following aromatase inhibitors administration in
women with breast cancer were analyzed, as well as recent
trials investigating the effectiveness of existing antifracture
therapies in the prevention of AI-induced bone loss and
fractures. Recommendations of national and international
organizations and societies or experts’ opinions on this topic
were also evaluated.
Assessment of skeletal effects of aromatase inhibitors
Aromatase inhibitors decrease bone mass and density, and
increase fragility fractures incidence compared to tamoxifen
[16, 17]. In healthy postmenopausal women, the rate of
bone loss is about 1–2% per year [18]. The annual rate of
bone loss in postmenopausal women receiving treatment
with AIs because of breast cancer is elevated to around
2.5% [19]. Although AIs use is not standard in premeno-
pausal women, a study of the combination of anastrozole
with a GnRH agonist has shown an annual bone loss rate of
7.0% [20]. Induced menopause in young women following
adjuvant chemotherapy is associated with accelerated bone
loss which has been estimated up to 8% at 1 year [21]; bone
loss is much higher in patients treated with AIs than in
osteoporotic postmenopausal women [20, 22]. It is estimat-
ed that more than 30% of patients treated with anastrozole
will have a diagnosis of osteoporosis in the subsequent years
[23]. Some variations concerning the magnitude of skeletal
side effects have been demonstrated between the different
aromatase inhibitors. A significant bone loss in patients trea-
ted with anastrozole occurred both at spine (from −2%
at 1 year up to −7% at 5 years) and hip (from −1% at
1 year up to −8% at 5 years), while a positive effect on BMD
was observed for tamoxifen, a SERM [23]. A 2–4% BMD
reduction at lumbar spine after 1 year on anastrozole was
found in an indirect comparison of the ATAC, IES and MA-
17 trials [24], while lower BMD reductions were reported in
other trials for letrozole (3% at 7 years) [9] and exemestane
(2% at 5 years) [24]. Cortical and trabecular bone at the radius
and tibia in postmenopausal women treated with anastrozole
for breast cancer was found to be lower using peripheral
quantitative computed tomography [25]. A comparative study
analyzing data from the same pivotal trials found significant
BMD reductions in patients under anastrozole: −2.3%,
−4.0%, 6.08% (at lumbar spine) and −1.5%, −3.9%, −7.2%
(total hip) after 1, 2, and 5 years, respectively [26]. Also,
treatment with letrozole resulted in significant bone loss:
−3.3% and −5.3% (lumbar spine), and −1.4% and
−3.6% (total hip) after the 1st and the 2nd year [26].
Decrease in BMD was apparently lower in patients treated
with exemestane, possibly related to its steroidal structure:
−1.7% and −1.0% (lumbar spine), and −1.4% and −0.8%
(total hip) at 6 and 24 months, respectively [26]. These data
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were confirmed in a recent meta-analysis showing significant
BMD reductions both at lumbar spine and total hip: −6.1%
and −7.2% for anastrozole at 5 years, −5.3% and −3.6%
for letrozole after 2 years, and −4.0% and −2.0% for
exemestane at 2 years [27]. Overall, there is a well-
documented AI class effect in decreasing bone mineral
density. This effect is of high magnitude and rapid. Estrogen
inhibition influences bone remodeling and increases osteo-
clastic activity, which is documented by an increase in bone
resorption markers, and finally results in bone loss [28]. On
the other hand, tamoxifen administration in postmenopausal
women with breast cancer has an opposite effect compared to
its use before menopause (where the estrogen deprivation
effect inducing bone loss is prevalent), thus resulting in a
small but significant BMD increase [29]. While this effect
has initially been deemed to be lower than with raloxifene [30,
31], the fracture incidence rates were found to be similar
between the two SERMs in a large primary prevention trial
(STAR) aimed at evaluating the preventive effect on breast
cancer of raloxifene versus tamoxifen in postmenopausal
women at risk for breast cancer [32]. A high incidence of
vertebral fractures has been observed in women with breast
cancer, mostly because of the premature menopause induced
by cancer chemotherapy [33].
Women treated with AIs present a more than 30%
higher risk of fractures compared to age-matched healthy
postmenopausal women [22]. However, among women trea-
ted with AIs, the population at higher risk of fracture is
younger than that normally observed in postmenopausal
women [34] and presents a lower baseline risk of fracture
[35]. This observation may explain why spontaneous fracture
incidence in the ATAC study [6] was found to be lower than
that observed in all major trials concerning osteoporotic frac-
tures [36–39]. Anastrozole was associated with a higher risk
of fracture at 5 years [40] and at 7 years compared with
tamoxifen [41]. Also, letrozole was associated with a long-
term (up to 5 years) higher risk of fracture if compared to
tamoxifen in the initial report of the BIG 1-98 trial (6.5% vs.
9.3%, respectively) [12] as well as in more recent reports
(5.7% vs. 4.0%) [42, 43]. The steroidal AI exemestane was
also associated with a higher risk of fragility fractures in
postmenopausal women with breast cancer after 1 year (7%
vs. 5%) and 3 years (3.1% vs. 2.3%) when compared to
tamoxifen [24, 44], with significant differences in BMD and
bone remodeling biomarkers [24, 44]. However, the effect on
the fracture risk was reversible when exemestane treatment
was stopped [46]. The effects of AIs on the incidence of
fragility fractures have been well documented as adverse
events within pivotal trials, with bone loss being directly
related to fracture risk increase [6, 16, 24, 27, 47, 48].
Table 1 summarizes the incidence of fragility fractures in main
clinical studies using aromatase inhibitors as adjuvant therapy
for breast cancer. Overall, the risk of fractures in patients
treated with AIs seems to be higher in peripheral skeletal sites
than spine or hip [43], a possible explanation for that being
represented by the younger age of patients if compared to the
studies carried out for the prevention of osteoporotic fractures
[36–39]. Importantly, fractures occurring in all the trials on
patients treated with AIs were reported as adverse events, thus
not representing primary endpoints of the studies, and possi-
bly producing an underestimation of spine and hip fracture
incidence. On the other hand, because the fracture rates related
to the use of AIs have almost always been reported in com-
parison to those of tamoxifen, this could overestimate the
difference in the incidence of both groups because of the
protective effect of tamoxifen on fracture risk. In addi-
tion, patients with breast cancer may have higher levels
of estrogens at baseline that could explain differences in
fracture incidence between patients treated with AIs and
those who are osteoporotic [49].
Management of patients receiving anti-aromatase
therapy
Calcium and vitamin D supplementation
Inwomen starting adjuvant treatment because of breast cancer,
serum concentrations of PTH, calcium, and 25-OH vitamin D
should be tested before starting any AI treatment. Actually,
vitamin D deficiency is very common among the general
population, including postmenopausal women [50–52].
Table 1 Fractures in adjuvant
studies with aromatase inhibitors
in breast cancer
aPatients initially randomized:
9,366 (treatment arm, anastra-
zole+tamoxifen, including
3,125 pts, was suppressed)
NR not reported
AI study Number Duration F/U, months Fractures (%) P value
Aromatase inhibitor Tamoxifen
ATAC6 6,241a 68 11.0 (anastrozole) 7.7 <.0001
BIG 1-9816 8,010 35.5 5.8 (letrozole) 4.1 .0006
IES24 4,742 30.6 3.1 (exemestane) 2.3 .08
ARNO48 3,224 28 2.4 (anastrozole) 1.2 NR
Placebo
MA.179 5,187 60 5 (letrozole) 5 .25
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Serum vitamin D levels at least above 75 nmol/l (30 ng/ml)
may be considered as a target, but many patients present
unrecognized vitamin D deficit at the time they are diagnosed
with breast cancer [53]. This deficiency has been associated
with a higher risk of cancer mortality in observational studies
[54, 55]. Secondary hyperparathyroidism resulting from low
serum concentrations of vitamin D might attenuate the anti-
resorptive action of bisphosphonates, thereby leading to a
higher risk of fractures if compared to patients with normal
levels of serum vitamin D [55, 56]. In conjunction with
calcium, an antifracture effect has been demonstrated for
vitamin D itself (at a dose of 700–800 IU/day), resulting in a
20% and 18% reduction of non-vertebral and hip fractures,
respectively [57]. However, there are no conclusive data in
breast cancer patients. Besides bone and muscle, other bene-
ficial effects of vitamin D have been suggested, but they still
remain controversial [53]. Beyond bone health, vitamin D has
been reported to exert positive effects in the prevention of
hypertension, cardiovascular diseases, falls, cancer incidence,
and mortality [53, 55]. Some vitamin D direct preventive
effects on breast cancer were reported by a recent metanalysis
[58], but results remain controversial [59]. The doses currently
used for vitamin D supplementation seem to be generally
insufficient to restore adequate serum concentration [52].
While the association between vitamin D levels and
breast cancer risk/prognosis is still controversial, the
U-shaped relationship between 25-OH vitamin D levels
and cancer or mortality risk observed in different studies
suggests the need to avoid both deficient and too high
levels [52, 60, 61]. A serum concentration of 25-OH
vitamin D ≥40 ng/ml was associated with lower inci-
dence of arthralgia in a specific prospective cohort
study specifically designed to establish optimal levels
of vitamin D for the prevention of AI-induced arthralgia
[62], while the risk of arthralgia in patients with low
concentration of 25-OH vitamin D (≤30 ng/ml) was confirmed
in a separate study [63]. A weekly dose of up to 10,000 IU
may thus be recommended in womenwith breast cancer based
on recent international guidelines [64].
Efficacy of antiresorptive therapies in the prevention
of AI-induced bone loss
Osteoporosis drugs used for the prevention of osteoporotic
fractures in postmenopausal osteoporosis have also been
proposed in women treated with AIs for breast cancer. An
open-label, multicentric, randomized trial (Zometa-Femara
Adjuvant Synergy Trial; Z-FAST/ZO-FAST) evaluated the
effect of concurrent administration of zoledronic acid i.v. at
a dose of 4 mg every 6 months (from the beginning of AI
treatment or as delayed additional therapy on the basis of
subsequent BMD values or in case of osteoporotic fracture)
and letrozole 2.5 mg per day over a 5-year period [65–70].
After 1 year, mean lumbar spine BMD increased by 1.9%
when compared with the baseline in patients who
started treatments with both zoledronic acid and letro-
zole from the beginning (upfront arm), while a −2.4%
reduction was observed in patients assigned to the
delayed treatment arm of the study [65–68]. The Z-FAST trial
enrolled 602 patients and showed an overall significant dif-
ference in lumbar spine BMD change of 4.4% at 1 year, which
increased up to 6.7% at 3 years [65, 69]. Similarly, the ZO-
FAST trial (1,066 patients enrolled) showed comparable
results, with an overall difference in lumbar spine BMD
change of 5.3% after 1 year, and 9.3% after 3 years in favor
of immediate concurrent administration of zoledronic acid and
letrozole [66–69]. Both Z-FAST and ZO-FAST studies have
shown that total hip BMD increased after 3 years in the
upfront treatment arm [65, 67]. Moreover, 3-year results from
the ZO-FAST study, showed a higher disease-free survival,
with a 41% risk reduction of disease recurrence in patients
who started concurrently letrozole and zoledronic acid
(upfront arm), compared to the delayed treatment arm [67].
This effect is confirmed in the ZO-FAST study 5-year follow-
up [70]. The efficacy of zoledronic acid in improving disease-
free survival and bone loss was also shown in premenopausal
patients in a 3-year study of the Austrian Breast and Colorectal
Study Group, involving 1,803 patients with hormone
receptor-positive breast cancer [71, 72]. In this open-label
randomized trial, concurrent administration of anastrozole or
tamoxifen and zoledronic acid 4 mg i.v. every 6 months
resulted in a significantly higher bone mineral density
(BMD remained stable over 3 years) if compared to that of
patients who did not receive zoledronic acid at all (where
marked decrease both in lumbar spine and total hip BMD
were observed) [71–73]. Interestingly, local and distant recur-
rences were reduced by zoledronic acid treatment [74], but the
results of the AZURE trial showed that adjuvant use of zole-
dronic acid did not improve disease-free survival (DFS) in
stage II/III breast cancer patients, at least in the whole group of
randomized patients [75]. The trial included 3,360 patients
from 174 centers in England who were randomized to receive
adjuvant chemotherapy and/or endocrine therapy with or
without zoledronic acid at 4 mg i.v. every 3 to 4 weeks for
six doses. The dose was then tapered down to every 3 months
for eight doses and then every 6 months for five doses to
complete 5 years of treatment. The addition of zoledronic acid
to standard treatment did not significantly impact the delivery
of chemotherapy [75]. Serious adverse events were similar in
both treatment arms, although there were 17 confirmed cases
of osteonecrosis of the jaw in the zoledronic acid arm
(P<.0001) [75]. The median follow-up was 5.9 months,
and 752 DFS events (377 in the zoledronic acid group
vs. 375 in the control group) have been reported.
Overall survival data showed a 15% reduction in risk of dying
with zoledronic acid, and this approached statistical
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significance (P0.07) [75]. Interestingly, a preplanned analysis
indicated that, when considering overall survival, the adjust-
ed Hazard Ratio (HR) was 1.01 for the premenopausal group
and 0.71 for the established postmenopausal women with a
significant 29% improvement (P0.017) [75].
Several studies have demonstrated the efficacy of
other bisphosphonates in preventing AI-associated bone
loss, although some of them are very small or present
inconclusive results. The ARIBON trial included 131
postmenopausal patients treated for 2 years with anastrozole
(plus calcium/vitamin D supplementation) [76]. Fifty osteo-
penic women were randomized to receive oral ibandronate
150 mg once a month or not. Ibandronate-treated women
showed positive BMD changes (+3.0% and +0.6% at lumbar
spine and total hip, respectively) when compared to those not
receiving ibandronate (−3.2% and −3.9% at lumbar spine and
total hip, respectively) [76]. The primary endpoint of the
SABRE study was to determine lumbar spine BMD changes
from baseline after 1 year of treatment with anastrozole alone
or in combination with risedronate (35 mg administered once
weekly) in 154 patients [77]. After 2 years, the results of the
SABRE study showed a +2.2% and +1.8% BMD increase at
lumbar spine and total hip, respectively, in the group treated
with risedronate [77]. Similar results were noted in older or
smaller trials (Table 2). However, risedronate failed in pre-
venting bone loss in 170 premenopausal women undergoing
adjuvant chemotherapy for breast cancer with anthracyclines,
taxanes, or cyclophosphamide [78]. Oral clodronate (at the
dose of 1,600 mg per day) has been demonstrated to improve
BMD at lumbar spine (+2.9%) and femoral neck (+3.7%) in a
study on 121 postmenopausal women with breast cancer [79].
Studies with alendronate have been performed on a very small
cohort of patients, thus leading to inconclusive results (not
significant increase in lumbar spine and hip BMD) [80, 81].
The effects of the new human monoclonal antibody denosu-
mab have also been explored. A trial has randomized 252 AI-
treated postmenopausal women with hormone receptor-
positive non-metastatic breast cancer to receive placebo or
denosumab 60 mg s.c. every 6 months [82]. After 2 years,
patients assigned to the treatment with denosumab had a
higher BMD than those in the placebo group, both at lumbar
spine (+7.6%) and total hip (+4.7%). A significant increase in
BMD with denosumab was observed at the lumbar spine after
1 year (+5.5%) and at the radius after 2 years (+6.1%) [82].
Available recommendations
There are few available recommendations. Since 2003,
ASCO has issued specific guidelines addressing the issue
of fracture prevention in postmenopausal women treated
with AIs [15, 83]. ASCO recommends that all patients with
T-score <−2.5 should undergo antifracture therapy with
bisphosphonates (i.e. alendronate, risedronate, or zoledronic
acid), without specific advice on treatment duration. ASCO
also recommends that the decision to treat patients with T-
scores between −1 and −2.5 should be tailored on an individ-
ual basis [83]. The issue of optimal treatment duration has
been addressed in 2008 by an international panel of experts
[84], which has suggested that patients should be treated for at
least 2 years, or possibly as long as AI therapy (up to 5 years),
by administering zoledronic acid at the dose of 4 mg i.v. every
6 months together with calcium and vitamin D supplementa-
tion. This panel of experts recommended to treat all people
with T-score e −2.0, and also those subjects presenting at least
two of the following risk factors: T-score <−1.5, age >65 years,
BMI <20 kg/m², family history of hip fracture, personal his-
tory of fragility fracture after 50 years of age, oral corticoste-
roid therapy >6 months, and cigarette smoking [84]. A recent
revision of these recommendations opens to the possibility of
using oral bisphosphonates by evaluating benefits and risks on
an individual basis [85]. In addition, denosumab is regarded as
a potential treatment option [85]. The international expert
panel suggested that the BMD of patients treated with oral
Table 2 Oral bisphosphonates for preventing AI-induced bone loss in postmenopausal women with early breast cancer
Antiresorptive
agent (trial)
Reference Number BMD
study n
Dosing Treatment
duration, years
Follow-up,
months
Mean change, % BMD
Lumbar
spine
Total hip
Clodronate Saarto [79] 61 61 1,600 mg PO/day 3 60 −1.0 −0.1
Risedronate (IBIS II) Singh et al. [91] 613 59 35 mg PO/week 5 12 +0.3 +0.7
Risedronate Confavreux [92] 118 11 35 mg PO/week 1 12 +4.1 +1.8
Risedronate Greenspan [93] 87 87 35 mg PO/week 2 24 +0.4 +0.9
Risedronate (ARBI) Markopoulos [94] 213 70 35 mg PO/week 2 24 +5.7 +1.6
Risedronate (SABRE) Van Poznak [95] 154 111 35 mg PO/week 2 24 +2.2 +1.8
Ibandronate (ARIBON) Lester [76] 131 50 150 mg PO/day 2 24 +3.0 +0.6
PO per os
Osteoporos Int (2012) 23:2567–2576 2571
bisphosphonates should be monitored every 1–2 years, while
the decision of the time interval for women undergoing i.v.
administration of zoledronic acid has not been clearly defined
[84]. On the other hand, postmenopausal women treated
with AIs who are not receiving any anti-osteoporotic
drug should undergo a BMD measurement after 1–2 years
of AI therapy and a regular assessment of their risk status [84,
85]. Therefore, as long as antiresorptive therapy to prevent
additional bone loss is initiated, osteoporosis (with or
without a history of fractures) is not a contraindication
for AI therapy in postmenopausal women with early
breast cancer [84, 85]. The panel recommended that
antiresorptive therapy should be continued as long as
AI therapy is maintained, currently most often 5 years
[84, 85]. The preference was given to zoledronic acid
4 mg i.v. every 6 months since it is the only antire-
sorptive agent with demonstrated efficacy and safety
over such a long duration [84, 85].
A consensus of the “Belgian Bone Club” suggested treat-
ing all patients with T-score <−2.5 or <−1 who also present
other clinical risk factors with i.v. zoledronic acid (as first
choice drug), or with oral bisphosphonates, for the duration
of AI therapy, providing adequate calcium and vitamin D
supplementation at the same time [86]. A UK expert group
considered all bisphosphonates as appropriate (zoledronic
acid 4 mg i.v. every 6 months, oral ibandronate 150 mg per
os every month or 3 mg i.v., oral alendronate 70 mg weekly,
oral risedronate 35 mg weekly), with the decision to treat
being based on the sole BMD value (T-score <−2.0), or
the occurrence of a vertebral fracture, or an annual bone
loss >4% (at lumbar spine or total hip) for T-score
between −1.0 and −2.0 and the presence of risk factors
(i.e., age >65 years; BMI <20 kg/m²; family history of
hip fracture; personal history of fragility fracture; corti-
costeroid therapy >6 months; cigarette smoking). Elderly
women (>75 year) with at least one risk factor should
be treated with a bisphosphonate irrespective of BMD
[87]. According to the same UK expert group, premen-
opausal women with ovarian suppression undergoing AI
therapy should receive a proper antifracture drug if their
T-score is <−1.0 or in case of vertebral fracture [87].
ESCEO working group guidance
There is clear evidence for an association between increased
bone loss and risk of fragility fractures and the administra-
tion of AIs to postmenopausal women with breast cancer.
Despite the growing recognition of the frequency and the
consequences of AI-induced bone loss, there are currently
no therapies specifically approved for its prevention. We
recommend that all women starting a therapy with AIs
should be carefully assessed for their baseline risk of oste-
oporotic fractures by performing a DXA examination and a
full evaluation of all clinical risk factors (including age,
parental fracture history, BMI <20 kg/m², corticosteroid
use, cigarette smoking, inadequate nutritional intakes, dis-
use, tendency to falls, and conditions associated to osteopo-
rosis). A biochemical survey should include determination
of calcium, PTH, and vitamin D levels, to exclude primary
hyperparathyroidism and to diagnose vitamin D insufficien-
cy or deficiency [53–55]. The role of biochemical markers
of bone turnover should be further investigated to assess
their ability to predict and possibly monitor bone loss in this
setting. General recommendations include an increase in
physical exercise and, in most patients, administration of
supplemental vitamin D (a weekly dose of up to 10,000 or
>800 IU/day) and calcium to maintain a calcium intake of at
least 1,000 mg/day.
BMD assessment by DXA and FRAX algorithm for the evaluation of clinical risk factors* 
Calcium, PTH and 25-OH-Vitamin D Levels, (Markers of bone turnover)  
General Measures  
suggest physical exercise and consider administration of vitamin D supplementation 
 (> 800 IU/per day or 10.000 IU per week) plus calcium (intake of at least 1000 mg/day)
Pre-menopausal women 
with ovarian suppression 
undergoing tamoxifen or AI 
therapy with T-score  < -1.0 
or presence of ≥ 1 vertebral 
fracture or   history of 
fragility fracture (any site,
irrespective to BMD)
Post-menopausal 
women with history of 
personal fragility 
fracture (any site) or
Age ≥ 75 years old 
(irrespective to BMD)
Post-menopausal women 
with T-score < -2.5              
or <-1.5 + ≥ 1 clinical risk 
factor or T-score < -1.0           
+ ≥ 2  clinical risk factors 
or FRAX 10-year risk            
of hip fracture ≥3% 
Antiresorptive treatment with zoledronic acid 4mg i.v. every 6 months denosumab s.c., or possibly oral 
bisphosphonates (with caution to patients compliance to therapy) for the entire period of AI treatment 
Fig. 1 Algorithm describing the suggested approach to patients with breast cancer treated with AIs
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Premenopausal women with ovarian suppression undergo-
ing tamoxifen or AI therapy should also receive antiresorptive
therapy if their T-score is <−1.0 or in case of vertebral fracture.
However, existing guidelines for antiresorptive therapy in
postmenopausal women do not lead to uniform recommenda-
tions and are often too complex (including those from the UK
expert group). Bisphosphonate therapy is recommended not
only in osteoporotic patients, but also in osteopenic patients, if
some of the above-mentioned risk factors for fractures are
present. BMD measurement by DXA is the cornerstone of
all recommendations, but the cutoffs vary. Which risk factors
used to help in the therapeutic decision are even more vari-
able, as well as their number. A key advance in predicting
fracture risk in postmenopausal women has been the develop-
ment of theWHO FRAX algorithm, which provides a 10-year
fracture probability [88]. However, FRAX is not designed to
assess fracture risk in women with breast cancer and indeed
may substantially underestimate the effect of AI therapy, as
the “secondary osteoporosis” option in the FRAX tool has a
much smaller effect on fracture risk than would be expected
for AI therapy and is entirely captured in BMD results [80].
Moreover, AIs have a large effect on fracture risk during
active treatment, which will be underestimated by FRAX.
FRAX is nevertheless useful to assess “baseline” fracture risk
in women about to start AI therapy. FRAX-based fracture risk
assessment without BMD assessment is markedly influenced
by a combination of age and prevalent fragility fracture [89].
On the basis of these considerations, we recommend that
antiresorptive treatment should be started in all osteoporotic
women and—irrespective of BMD—in all women older than
75 years, and patients with a prevalent fragility fracture.
Although the evidence is less strong, postmenopausal women
with T-score <−1.5 presenting at least one clinical risk factor
(including age, parental fracture history, BMI <20 kg/m²,
corticosteroids use, cigarette smoking, inadequate nutritional
intakes, disuse, tendency to falls, and conditions associated to
osteoporosis) should be treated, as well as those with a T-score
between −1 and −1.5 presenting at least two clinical risk
factors (Fig. 1). Alternatively, therapy could be considered in
patients with a FRAX-determined 10-year hip fracture prob-
ability ≥3%, which corresponds to the intervention threshold
suggested in many countries (or a probability for major oste-
oporotic fractures of 20%).
Most data have been obtained with zoledronic acid 4 mg
i.v. every 6 months [86]. Oral bisphosphonates given at the
licensed anti-osteoporotic doses appear to be able to prevent
AI-induced bone loss and indeed represent a valid therapeutic
option. However, a critical issue is patients’ adherence to oral
antifracture therapy, and a switch to intravenous therapy is
recommended if non-adherence to oral therapy is suspected.
Moreover, oral bisphosphonates have been studied in much
smaller trials than zoledronic acid. There is also some evi-
dence that zoledronic acid reduces tumor recurrence rate in
pre- or postmenopausal women receiving AI therapy [67], and
its efficacy in the prevention of AI-induced bone loss is
already well documented [65–73]. Such an effect, in terms
of recurrence reduction, has not been reported so far in breast
cancer for other antiresorptives, notably denosumab, which
represents a new effective treatment option more effective
than zoledronic acid in patients with bone metastases [90].
The duration of bisphosphonate or denosumab therapy should
be as long as that of AI administration, although the prolonged
effect of zoledronic acid on bone mass is an argument for a
shorter (i.e., 3 years) treatment duration [65–69].
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